HRP20140204T1 - Oralni oblici doziranja bendamustina - Google Patents

Oralni oblici doziranja bendamustina Download PDF

Info

Publication number
HRP20140204T1
HRP20140204T1 HRP20140204AT HRP20140204T HRP20140204T1 HR P20140204 T1 HRP20140204 T1 HR P20140204T1 HR P20140204A T HRP20140204A T HR P20140204AT HR P20140204 T HRP20140204 T HR P20140204T HR P20140204 T1 HRP20140204 T1 HR P20140204T1
Authority
HR
Croatia
Prior art keywords
pharmaceutical preparation
preparation according
minutes
bendamustine
corticosteroid
Prior art date
Application number
HRP20140204AT
Other languages
English (en)
Croatian (hr)
Inventor
Jeffrey Colledge
Margaretha Olthoff
Original Assignee
Astellas Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40588059&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20140204(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Deutschland Gmbh filed Critical Astellas Deutschland Gmbh
Publication of HRP20140204T1 publication Critical patent/HRP20140204T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HRP20140204AT 2008-12-03 2009-12-03 Oralni oblici doziranja bendamustina HRP20140204T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08075915 2008-12-03
PCT/EP2009/008857 WO2010063493A1 (en) 2008-12-03 2009-12-03 Oral dosage forms of bendamustine

Publications (1)

Publication Number Publication Date
HRP20140204T1 true HRP20140204T1 (hr) 2014-04-11

Family

ID=40588059

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140204AT HRP20140204T1 (hr) 2008-12-03 2009-12-03 Oralni oblici doziranja bendamustina

Country Status (25)

Country Link
US (4) US20120003305A1 (enExample)
EP (1) EP2367542B1 (enExample)
JP (1) JP5778037B2 (enExample)
KR (1) KR101688038B1 (enExample)
CN (2) CN105363037B (enExample)
AU (1) AU2009321745B2 (enExample)
BR (1) BRPI0922806B8 (enExample)
CA (1) CA2745525A1 (enExample)
CO (1) CO6400183A2 (enExample)
CY (1) CY1114977T1 (enExample)
DK (1) DK2367542T3 (enExample)
EA (1) EA020354B1 (enExample)
ES (1) ES2451540T3 (enExample)
HR (1) HRP20140204T1 (enExample)
IL (1) IL213270A (enExample)
MX (1) MX2011005643A (enExample)
NZ (1) NZ592970A (enExample)
PL (1) PL2367542T3 (enExample)
PT (1) PT2367542E (enExample)
RS (1) RS53201B (enExample)
SI (1) SI2367542T1 (enExample)
SM (1) SMT201400053B (enExample)
UA (1) UA102120C2 (enExample)
WO (1) WO2010063493A1 (enExample)
ZA (1) ZA201103791B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011260615B2 (en) * 2010-06-02 2016-11-17 Pharma& Schweiz Gmbh Oral dosage forms of bendamustine
JO3659B1 (ar) 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
CN102375044B (zh) * 2010-08-18 2015-04-08 重庆华邦胜凯制药有限公司 一种盐酸苯达莫司汀中间体z6有关物质的分析方法
ES2613838T3 (es) * 2011-09-26 2017-05-26 Fresenius Kabi Oncology Ltd Un procedimiento mejorado para la preparación de hidrocloruro de bendamustina
AU2012332767C1 (en) * 2011-10-31 2017-02-02 Genentech, Inc. Antibody formulations
EP2641592A1 (en) 2012-03-23 2013-09-25 Salmon Pharma GmbH Pharmaceutical formulation comprising bendamustine
PT2656843E (pt) 2012-04-26 2015-04-14 Helmut Schickaneder Ésteres de bendamustina e compostos relacionados e a sua utilização médica
EP2917183A1 (en) * 2012-11-12 2015-09-16 Ignyta, Inc. Bendamustine derivatives and methods of using same
CA2904143A1 (en) 2013-03-12 2014-10-09 Cephalon, Inc. Nanoparticulate and macroparticulate formulations
JP2016153374A (ja) * 2013-06-25 2016-08-25 シンバイオ製薬株式会社 炎症性疾患を治療又は予防するための医薬組成物
CN109953954A (zh) 2013-08-27 2019-07-02 V·沃道里斯 苯达莫司汀医药组合物
AU2018346395A1 (en) 2017-10-05 2020-04-30 Mecox Curemed Co., Ltd. Oral bendamustine formulations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US132502A (en) * 1872-10-22 Improvement in machines for removing snow from railroads
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US20030105141A1 (en) * 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
CN101052396A (zh) * 2004-11-05 2007-10-10 赛福伦公司 癌症治疗
EP1814544A4 (en) * 2004-11-05 2009-12-02 Cephalon Inc CANCER TREATMENTS
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
CN101119708B (zh) * 2005-01-14 2014-12-24 赛福伦公司 苯达莫司汀冻干药物组合物
CN101028249A (zh) * 2007-04-12 2007-09-05 济南康泉医药科技有限公司 一种含新生血管抑制剂及烷化剂的抗癌组合物
CN101045058A (zh) * 2007-04-28 2007-10-03 济南帅华医药科技有限公司 一种含烷化剂及激素类药物的抗癌组合物
CN101084876A (zh) * 2007-07-11 2007-12-12 济南康泉医药科技有限公司 一种含苯达莫司汀的抗癌组合物
US20090130198A1 (en) * 2007-11-21 2009-05-21 Innopharmax Inc. Pharmaceutical composition with enhanced bioavailability
US8349353B2 (en) * 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders

Also Published As

Publication number Publication date
EA020354B1 (ru) 2014-10-30
CA2745525A1 (en) 2010-06-10
WO2010063493A1 (en) 2010-06-10
BRPI0922806B8 (pt) 2021-05-25
AU2009321745A1 (en) 2011-06-23
KR101688038B1 (ko) 2016-12-20
AU2009321745B2 (en) 2016-06-23
SMT201400053B (it) 2014-07-07
US20120003305A1 (en) 2012-01-05
NZ592970A (en) 2013-05-31
CN102281871A (zh) 2011-12-14
CY1114977T1 (el) 2016-12-14
RS53201B (sr) 2014-06-30
IL213270A (en) 2017-05-29
IL213270A0 (en) 2011-07-31
CN105363037B (zh) 2019-02-05
CN105363037A (zh) 2016-03-02
MX2011005643A (es) 2011-09-27
BRPI0922806B1 (pt) 2020-03-03
SI2367542T1 (sl) 2014-05-30
PL2367542T3 (pl) 2014-05-30
PT2367542E (pt) 2014-03-10
US20170095452A1 (en) 2017-04-06
US10543196B2 (en) 2020-01-28
EP2367542B1 (en) 2014-01-01
EA201190011A1 (ru) 2012-02-28
BRPI0922806A2 (pt) 2015-12-22
US20140018334A1 (en) 2014-01-16
US20150335588A1 (en) 2015-11-26
CO6400183A2 (es) 2012-03-15
JP5778037B2 (ja) 2015-09-16
ZA201103791B (en) 2012-07-25
KR20110102393A (ko) 2011-09-16
JP2012510484A (ja) 2012-05-10
DK2367542T3 (da) 2014-03-10
ES2451540T3 (es) 2014-03-27
UA102120C2 (ru) 2013-06-10
EP2367542A1 (en) 2011-09-28

Similar Documents

Publication Publication Date Title
JP2012510484A5 (enExample)
EP4096671B1 (en) Combination therapy for treating abnormal cell growth
RU2743643C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
TWI841481B (zh) 乳酸鈣組成物及使用方法
JO3659B1 (ar) أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
JP2020505433A5 (enExample)
CA3080644A1 (en) Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
JP2018508516A5 (enExample)
Villanueva et al. A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study
JP2015504924A5 (enExample)
JP2019530706A5 (enExample)
JP2018503610A5 (enExample)
TWI883565B (zh) 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
CN108697725A (zh) 组合疗法
WO2024102187A1 (en) Combination therapy comprising bispecific antibodies comprising an nrp1 binding domain
KR20210010524A (ko) 샘낭암종을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조성물
WO2006045541A1 (en) Treatment and prevention of multi-drug resistance
CN112535688A (zh) 药物组合
US20260053814A1 (en) Treatment regimens for gedatolisib in hormonally-driven disorders
KR20250145693A (ko) 미토겐 활성화 단백질 키나제(mapk) 경로 변경을 이용한 고형 종양의 치료 방법
Rummel German experience with bendamustine treating Relapsed/Refractory indolent B-Cell and mantle cell lymphomas
RU2777519C2 (ru) Применение ингибитора parp в лечении резистентного к химиотерапии рака яичников или рака молочной железы
US20240342157A1 (en) Bak activators, pharmaceutical compositions, and uses in treating cancer
CN103561745A (zh) 用于治疗癌症的药剂和方法
Friedberg The US clinical experience with bendamustine